ArticleBMC cardiovascular disorders2026
Assessing the clinical impact of albumin infusion in critically ill ICU patients with acute myocardial infarction and hypoalbuminemia: a retrospective propensity score-matched cohort study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe clinical impact of exogenous albumin supplementation in critically ill hypoalbuminemic patients with acute myocardial infarction (AMI) remains uncertain.
methodsThis retrospective cohort study utilized the MIMIC-IV (Medical Information Mart for Intensive Care-IV) database. Adult ICU patients with AMI and hypoalbuminemia were included. Albumin infusion during the ICU stay was considered clinician-driven supportive therapy rather than a protocol-directed intervention. Propensity score matching (PSM) was performed in a 1:1 ratio, yielding 153 patients in the albumin group and 153 matched controls. The primary outcomes were 30-day and 90-day all-cause mortality. Secondary outcomes included ICU and hospital length of stay. Multivariable regression analyzes were performed to adjust for potential confounders.
resultsThe pre-matched cohort included 1,285 patients. After PSM, 306 patients (153 per group) with balanced baseline characteristics were included in the analysis. No significant differences were observed in 30-day mortality (34.0% vs. 35.9%, p = 0.719) or 90-day mortality (45.8% vs. 45.1%, p = 0.909). Cox regression showed no independent association between albumin infusion and 30-day mortality (HR 0.85; 95% CI 0.57–1.27; p = 0.429) or 90-day mortality (HR 0.97; 95% CI 0.68–1.37; p = 0.843). However, albumin infusion was associated with longer ICU stay (β = 4.34 days; 95% CI 2.91–5.76; p < 0.001) and hospital stay (β = 4.43 days; 95% CI 1.12–7.74; p = 0.009).
conclusionIn critically ill hypoalbuminemic patients with AMI, albumin infusion was not associated with reduced short-term mortality but was associated with longer ICU and hospital stays, likely reflecting greater illness severity rather than a causal treatment effect. Further prospective studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.